Background: Beta-based adaptive Deep Brain Stimulation (aDBS) is effective in Parkinson's disease (PD), when assessed in the immediate post-implantation phase. However, the potential benefits of aDBS in patients with electrodes chronically implanted, in whom changes due to the microlesion effect have disappeared, are yet to be assessed. Methods: To determine the acute effectiveness and side-effect profile of aDBS in PD compared to conventional continuous DBS (cDBS) and no stimulation (NoStim), years after DBS implantation, 13 PD patients undergoing battery replacement were pseudo-randomised in a crossover fashion, into three conditions (NoStim, aDBS or cDBS), with a 2-min interval between them. Patient videos were blindly evaluated using a short version of the Unified Parkinson's Disease Rating Scale (subUPDRS), and the Speech Intelligibility Test (SIT). Results: Mean disease duration was 16 years, and the mean time since DBS-implantation was 6.9 years. subUPDRS scores (11 patients tested) were significantly lower both in aDBS (p=
CITATION STYLE
Piña-Fuentes, D., van Dijk, J. M. C., van Zijl, J. C., Moes, H. R., van Laar, T., Oterdoom, D. L. M., … Beudel, M. (2020). Acute effects of adaptive Deep Brain Stimulation in Parkinson’s disease. Brain Stimulation, 13(6), 1507–1516. https://doi.org/10.1016/j.brs.2020.07.016
Mendeley helps you to discover research relevant for your work.